Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Meningioma 1

Interventions

Specimen Handling 16Biopsy 11Magnetic Resonance Spectroscopy 10Taxes 4Bevacizumab 4Cyclophosphamide 3Cetuximab 3olaparib 2decitabine and cedazuridine drug combination 2Vincristine 2Prednisone 2Paclitaxel 2Immunoglobulin G 2Gemcitabine 2Doxorubicin 2Disulfides 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2(225)Ac-DOTA-c(RGDyK) 2zimberelimab 1zanubrutinib 1trastuzumab deruxtecan 1taletrectinib 1spartalizumab 1sotigalimab 1relatlimab 1regorafenib 1prednylidene 1neratinib 1mirdametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Hydroxyurea × 30 days × Clear all
NCT06955169 2026-05-22

MOMENTUM-1

RTOG Foundation, Inc.

Phase 2 Suspended
153 enrolled
CNS

Meningioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡